Preclinical Safety Assessment and Mitigation Strategies in Drug Discovery - Focus on Drug-Induced Liver Injury (DILI)

17 October 2018

Event overview

15:00-16:00 GMT (London)
10:00-11:00 AM ET (New York)

A challenging aspect of drug discovery is the mitigation of safety risks that arise during most drug discovery optimization efforts.  This webinar will highlight some of the current best practices and methods used in pharma to identify, understand and mitigate common preclinical safety risks.   It will also explore proactive approaches that may help drug-hunters avoid many safety issues on the road to clinical candidate selection and first human dose.  There will be specific emphasis on assessing and mitigating risks associated with drug-induced liver injury (DILI).  Several DILI-related mechanisms, such as BSEP inhibition, bioactivation and reactive metabolite formation will be discussed.

While the focus is on medicinal chemistry methods, this webinar will benefit all scientists who participate in the cross functional execution of drug discovery programs.

This FREE webinar will be presented by Dr Bryan Norman. Bryan is the tutor on the 2-day course: Preclinical Safety Assessment and Mitigation Strategies in Drug Discovery.

15:00-16:00 GMT (London)
10:00-11:00 AM ET (New York)

Become a speaker at one of our events

Share your expertise with a global audience of industry professionals. Scientific Update is continually seeking thought leaders and industry innovators to speak at our renowned conferences and training courses.

Preclinical Safety Assessment and Mitigation Strategies in Drug Discovery - Focus on Drug-Induced Liver Injury (DILI)

17 October 2018

Webinar recording

Please enter your email address to access this recording.

Download slides

Please enter your email address to access these slides.